Investment Ratings
-
Master Rating:
-
Panacea Biotec (Nse) has an operating revenue of Rs. 674.65 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of -23% needs improvement, NULL The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 3 which is a POOR score indicating inconsistency in earnings, a RS Rating of 3 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 146 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Analyst Recommendation : HOLD
Panacea Biotec Ltd Forecast
Price Estimates
Eps And Sales Estimates
Panacea Biotec Ltd Synopsis
NSE-Medical-Generic Drugs
Panacea Biotec L is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 343.56 Cr. and Equity Capital is Rs. 6.13 Cr. for the Year ended 31/03/2021. Panacea Biotec Ltd. is a Public Limited Listed company incorporated on 02/02/1984 and has its registered office in the State of Punjab, India. Company’s Corporate Identification Number(CIN) is L33117PB1984PLC022350 and registration number is 022350.-
Market Cap
INR 1,240.95 Cr
-
Sales
INR 304.40 Cr
-
Shares in Float
1.59 Cr
-
No of Funds
3 K
-
Yield
%
-
Book Value
2.54
-
U/D Vol Ratio
0.5
-
LTDebt/Equity
12%
-
Alpha
-0.07
-
Beta
0.77
| Owner Name | Jun-21 | Mar-21 | Dec-20 |
|---|---|---|---|
| Promoters | 73.59% | 73.59% | 73.59% |
| Mutual Funds | 0% | 1.27% | 1.28% |
| Foreign Portfolio Investors | 0.03% | 0.1% | 0.05% |
| Individual Investors | 15.21% | 17.33% | 16.01% |
| Others | 11.17% | 7.71% | 9.07% |
| Name | Designation |
|---|---|
| Mr. Soshil Kumar Jain | Chairman |
| Dr. Rajesh Jain | Managing Director |
| Mr. Sandeep Jain | Joint Managing Director |
| Mr. Ankesh Jain | Director - Sales & Marketing |
| Mr. R L Narasimhan | Non Executive Director |
| Mr. N N Khamitkar | Non Executive Director |
| Mr. K M Lal | Non Executive Director |
| Mrs. Manjula Upadhyay | Non Executive Director |
| Mr. Bhupinder Singh | Non Executive Director |
| Mr. Shantanu Yeshwant Nalavadi | Non Executive Director |
Panacea Biotec Ltd Financials
- Quarterly P&L
- Annual P&L
- Cash Flow
- Balance Sheet
- Ratios
| INDICATOR | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 119.26 | 36.26 | 79.86 | 69.02 | 118.2 |
| Operating Expenses Qtr Cr | 136.71 | 55.67 | 95.97 | 65.75 | 102.34 |
| Operating Profit Qtr Cr | -17.45 | -19.41 | -16.11 | 3.27 | 15.86 |
| Depreciation Qtr Cr | 6.48 | 6.43 | 6.57 | 6.64 | 6.69 |
| Interest Qtr Cr | 1.91 | 1.78 | 1.86 | 1.89 | 1.99 |
| Tax Qtr Cr | 0 | 0 | 1.52 | 0.01 | 0.01 |
| Net Profit Qtr Cr | -22.37 | -23.47 | -18.31 | 1.9 | 10.81 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total Revenue Annual Cr | 364.303 | 188.96 | 99.735 | 196.218 | 583.751 |
| Operating Expenses Annual Cr | 343.067 | 220.316 | 242.873 | 191.822 | 460.602 |
| Operating Profit Annual in Cr | 0.488 | -62.231 | -146.663 | -8.105 | 69.485 |
| Depreciation Cr | 26.571 | 26.905 | 33.03 | 33.694 | 66.147 |
| Interest Annual Cr | 7.517 | 5.267 | 104.633 | 103.228 | 103.504 |
| Tax Annual Cr | 1.561 | 17.099 | 10.608 | 10.642 | -11.382 |
| Net Profit Annual Cr | -14.441 | -153.07 | 26.57 | -71.876 | -72.661 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Cash from Operating Activity Annual Cr | 38.266 | -82.855 | 107.155 | 172.059 | 103.835 |
| Cash from Investing Activity Annual Cr | -37.323 | -18.518 | -8.331 | -2.73 | -17.923 |
| Cash from Financing Annual Activity Cr | -7.202 | 109.393 | -98.454 | -163.668 | -91.062 |
| Net Cash Flow Annual Cr | -6.259 | 8.02 | 0.37 | 5.661 | -5.15 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total ShareHolders Funds Annual Cr | 489.96 | 873.837 | 419.377 | 387.918 | 454.668 |
| Fixed Assets Annual Cr | 477.218 | 503.016 | 499.542 | 928.089 | 969.698 |
| Total Non Current Assets Annual Cr | 499.02 | 524.169 | 525.928 | 1319.837 | 1372.377 |
| Total Current Assets Annual Cr | 292.548 | 614.319 | 916.107 | 353.651 | 409.374 |
| Total Assets Annual Cr | 791.568 | 1138.488 | 1442.035 | 1673.488 | 1781.751 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Book Value Per Share Annual Rs | 79.4305 | 142.1942 | 66.7482 | 61.789 | 72.8458 |
| ROE Annual % | -2.96 | -17.57 | 6.49 | -18.99 | -16.28 |
| ROCE Annual % | -0.9 | -6.01 | -33.81 | -2.96 | 4.78 |
| Total Debt to Total Equity Annual | - | - | - | - | - |
| EBDIT Annual Margin % | 6.18 | -19.83 | -148.77 | 2.39 | 23.23 |
Panacea Biotec Ltd Technicals
EMA & SMA
CURRENT PRICE
202.6 
(0.57)
-
- Bullish Moving Averages 1
- Bearish Moving Averages 15
EMA
-
20 Day
208.41
-
50 Day
228.9
-
100 Day
253.65
-
200 Day
288.31
Panacea Biotec Ltd Resistance and support
204.89 PIVOT
-
First Resistance
208.32
-
Second Resistance
215.19
-
Third Resistance
218.62
-
First Support
198.02
-
Second Support
194.59
-
Third Support
187.72
-
RSI
44.74
-
MFI
43.8
-
MACD
-3.95
-
MACD signal line
-7.21
Panacea Biotec Ltd Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 103,952 | 5,293,236 | 50.92% |
| Week | 217,329 | 13,281,000 | 61.11% |
| 1 Month | 206,936 | 11,091,785 | 53.6% |
| 6 Month | 226,554 | 11,067,153 | 48.85% |
Panacea Biotec Ltd Price change analysis
-6.25
Over 1 month
Low High 163.8 237
-106.35
Over 3 month
Low High 163.8 311.55
-179.9
Over 6 months
Low High 163.8 412.3
-25.15
Over Year
Low High 163.8 453.7Similar Stocks
| Company Name | 52 Week () |
Market Price () | Volume |
|---|---|---|---|
| Jagsonpal Pharmaceuticals Ltd | 203.25 | 155.05 (0.68%) | 2856 |
| Hikal Ltd | 742.00 | 513.90 (1.62%) | 21474 |
| Sanofi India Ltd | 9,300.00 | 7,695.00 (-1.02%) | 1054 |
| Ami Organics Ltd | 1,438.50 | 982.15 (1.07%) | 18718 |
News
PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under
This is with reference to CDSL's Operating Instructions for Issuers/RTAs, which states that the Issuer/RTA shall inform the details of the s Read More
Panacea Biotec Ltd - 531349 - Clarification On Movement In P
We would like to state as under: 1. The Company has made all the necessary disclosures pursuant to Regulation 30 of the SEBI (Listing Obliga Read More
Panacea Biotec Ltd - 531349 - Clarification sought from Pana
The Exchange has sought clarification from Panacea Biotec Ltd on December 2, 2021 with reference to significant movement in price, in order Read More
Panacea Biotec Ltd - 531349 - Clarification On News Item App
We would like to state as under: 1. The Company's WOS, Panacea Biotec Pharma Limited ('PBPL') has issued Series 1A, Series 1B and Series 3 N Read More
Panacea Biotec Ltd - 531349 - Announcement under Regulation
In continuation to our letter dated November 12, 2021 for approving the Unaudited Standalone and Consolidated Financial Results (Provisional Read MoreBlogs